Connaughton Bernadette 4

What Happened
Bernadette Connaughton, a member of the board of directors at Halozyme Therapeutics, sold 1,625 shares of HALO on June 1, 2026 at $66.21 per share, generating proceeds of $107,591. The sale is reported as an S (sale) transaction and was executed pursuant to a written trading plan.

Key Details

• Transaction date and price: June 1, 2026 — 1,625 shares at $66.21 each.
• Total proceeds: $107,591.
• Shares owned after the transaction: Not disclosed in the provided filing excerpt.
• Footnote: Sale made under a written Rule 10b5-1 trading plan adopted May 29, 2025.
• Filing date: Form 4 filed June 2, 2026 — appears timely (Form 4s are generally due within two business days).

Context
Sales executed under prearranged 10b5-1 plans are typically scheduled in advance and are often routine liquidity transactions; they do not, by themselves, indicate current insider sentiment about the company. For retail investors, purchases usually carry more direct informational weight than routine sales.